Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Jonathan G. Drachman, insider at Neoleukin Therapeutics
Jonathan G. Drachman Insider Alerts

Get notified the next time Jonathan G. Drachman buys or sells Neoleukin Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Jonathan G. Drachman Insider Information

Dr. Drachman is a seasoned clinician, researcher, and biopharmaceutical executive who joined Neoleukin at the company’s founding in 2018. For 14 years prior, he was at Seattle Genetics, where he most recently served as Chief Medical Officer and Executive Vice President of Research and Development. From 1998 to 2004, Dr. Drachman was a faculty member of the Division of Hematology at the University of Washington in Seattle, and a Senior Investigator in the Division of Research and Education at Puget Sound Blood Center. He currently serves on the board of directors for Calithera Biosciences and Harpoon Therapeutics. Dr. Drachman received a BA in Biochemistry from Harvard University and an MD from Harvard Medical School. He completed his residency in internal medicine and fellowship in medical oncology at the University of Washington.

What is Jonathan G. Drachman's net worth?

The estimated net worth of Jonathan G. Drachman is at least $12.24 million as of August 24th, 2021. Dr. Drachman owns 2,348,686 shares of Neoleukin Therapeutics stock worth more than $12,236,654 as of December 5th. This net worth evaluation does not reflect any other assets that Dr. Drachman may own. Learn More.

What is Jonathan G. Drachman's salary?

As the CEO of Neoleukin Therapeutics, Inc., Dr. Drachman earned a total compensation package of $4,468,538.00 in 2020. Dr. Drachman earned a salary of $418,750.00, non-equity compensation of $219,680.00, and no other miscellaneous compensation.

How do I contact Jonathan G. Drachman?

The corporate mailing address for Dr. Drachman and other Neoleukin Therapeutics executives is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. Neoleukin Therapeutics can also be reached via phone at (866) 245-0312 and via email at [email protected]

Has Jonathan G. Drachman been buying or selling shares of Neoleukin Therapeutics?

Jonathan G. Drachman has not been actively trading shares of Neoleukin Therapeutics during the last ninety days. Most recently, on Tuesday, August 24th, Jonathan G. Drachman bought 100,000 shares of Neoleukin Therapeutics stock. The stock was acquired at an average cost of $6.11 per share, with a total value of $611,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,348,686 shares of the company's stock, valued at $14,350,471.46.

Who are Neoleukin Therapeutics' active insiders?

Neoleukin Therapeutics' insider roster includes Jonathan Drachman (CEO), and Carl Walkey (SVP).

Are insiders buying or selling shares of Neoleukin Therapeutics?

During the last year, Neoleukin Therapeutics insiders bought shares 2 times. They purchased a total of 140,000 shares worth more than $990,200.00. During the last year, insiders at the sold shares 22 times. They sold a total of 34,097 shares worth more than $400,865.97. The most recent insider tranaction occured on August, 24th when CEO Jonathan G Drachman bought 100,000 shares worth more than $611,000.00. Insiders at Neoleukin Therapeutics own 10.9 % of the company.

Information on this page was last updated on 8/24/2021.

Jonathan G. Drachman Insider Trading History at Neoleukin Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2021Buy100,000$6.11$611,000.002,348,686View SEC Filing Icon  
6/3/2021Buy40,000$9.48$379,200.002,238,686View SEC Filing Icon  
See Full Table

Jonathan G. Drachman Buying and Selling Activity at Neoleukin Therapeutics

This chart shows Jonathan G Drachman's buying and selling at Neoleukin Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neoleukin Therapeutics Company Overview

Neoleukin Therapeutics logo
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
Read More

Today's Range

Now: $5.21
Low: $4.99
High: $5.24

50 Day Range

MA: $6.54
Low: $4.85
High: $7.75

2 Week Range

Now: $5.21
Low: $4.66
High: $17.95

Volume

284,303 shs

Average Volume

211,297 shs

Market Capitalization

$221.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!